Abstract

Radiolabeled immunoglobulin therapy (RIT) of human cancer continued to show considerable promise in the clinical and laboratory studies. Clinical trials using RIT are producing 50% complete remission rates in Hodgkin's disease at Johns Hopkins, and other institutes report excellent response with B-cell lymphoma. The response of other tumors is less pronounced. The laboratory studies that have been completed under this research program have not only identified mechanisms that influence the therapeutic ratio of RIT,but also offer specific research directions that may offer improved effects of RIT on a wider spectrum of human tumors.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA043791-04A1
Application #
3094071
Study Section
Special Emphasis Panel (SRC (O1))
Project Start
1987-09-01
Project End
1994-08-31
Budget Start
1991-09-26
Budget End
1992-08-31
Support Year
4
Fiscal Year
1991
Total Cost
Indirect Cost

  Institution

Name
Johns Hopkins University
Department
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218

  Publications

Quadri, S M; Vriesendorp, H M (1998) Effects of linker chemistry on the pharmacokinetics of radioimmunoconjugates. Q J Nucl Med 42:250-61
Vriesendorp, H M; Quadri, S M; Jaeckle, K A et al. (1996) Proposal for translational analysis and development of clinical radiolabeled immunoglobulin therapy. Radiother Oncol 41:151-61
Quadri, S M; Malik, A B; Chu, H B et al. (1996) Intraperitoneal indium-111- and yttrium-90-labeled human IgM (AC6C3-2B12) in nude mice bearing peritoneal carcinomatosis. J Nucl Med 37:1545-51
Vriesendorp, H M; Morton, J D; Quadri, S M (1995) Review of five consecutive studies of radiolabeled immunoglobulin therapy in Hodgkin's disease. Cancer Res 55:5888s-5892s
Quadri, S M; Siddiqui, A; Klein, J L et al. (1995) Biodistribution and tumor localization of 111In-labeled unmodified and modified F(ab')2 fragments of human monoclonal IgM (16.88) in a nude mouse model. Nucl Med Biol 22:413-23
Quadri, S M; Malik, A B; Tang, X Z et al. (1995) Preclinical analysis of intraperitoneal administration of 111In-labeled human tumor reactive monoclonal IgM AC6C3-2B12. Cancer Res 55:5736s-5742s
Dillehay, L E; Mayer, R; Zhang, Y G et al. (1995) Prediction of tumor response to experimental radioimmunotherapy with 90Y in nude mice. Int J Radiat Oncol Biol Phys 33:417-27
Mayer, R; Dillehay, L E; Shao, Y et al. (1995) Direct measurement of intratumor dose-rate distributions in experimental xenografts treated with 90Y-labeled radioimmunotherapy. Int J Radiat Oncol Biol Phys 32:147-57
Siddiqui, A; Quadri, S M; Griffiths, G L et al. (1995) Tumor targeting and pharmacokinetics of unmodified and modified F(ab)2 fragments of an anti-CEA murine monoclonal antibody (Immu-14). Nucl Med Biol 22:425-35
Herpst, J M; Klein, J L; Leichner, P K et al. (1995) Survival of patients with resistant Hodgkin's disease after polyclonal yttrium 90-labeled antiferritin treatment. J Clin Oncol 13:2394-400

Showing the most recent 10 out of 39 publications